Tim I M Korevaar1, Lidia Mínguez-Alarcón1, Carmen Messerlian1, Ralph A de Poortere2, Paige L Williams3,4, Maarten A Broeren2, Russ Hauser1,4, Irene C Souter5. 1. 1 Department of Environmental Health, Harvard T.H. Chan School of Public Health , Boston, Massachusetts. 2. 2 Laboratory of Clinical Chemistry and Hematology , Máxima Medical Centre, Veldhoven, The Netherlands . 3. 3 Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, Massachusetts. 4. 4 Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts. 5. 5 Vincent Obstetrics and Gynecology, Massachusetts General Hospital Fertility Center , Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: While overt thyroid disease is a well known risk factor for infertility, the potential consequences of mild thyroid dysfunction or thyroid autoimmunity remain unknown. Experimental studies suggest a considerable role for thyroid hormone in the physiological mechanisms of ovarian reserve, but translation of such findings to human studies remains rare. A potential role for thyroid function in female reproduction could be especially relevant when the cause of infertility remains unknown, such as in women with diminished ovarian reserve (DOR) or unexplained infertility. The aims of this study were to investigate the association of thyroid function and autoimmunity with markers of ovarian reserve day 3 follicle-stimulating hormone (FSH) concentrations and antral follicle count (AFC), and to investigate whether thyroid function or autoimmunity may have different effects in women with DOR or unexplained infertility. METHODS: Thyrotropin, free thyroxine, thyroxine, free triiodothyronine (fT3), triiodothyronine, thyroid peroxidase antibodies (TPOAbs), and thyroglobulin antibodies (TgAbs), as well as AFC and the day 3 FSH concentration, were measured among women seeking fertility treatment at the Massachusetts General Hospital Fertility Center. Multiple linear or mixed regression models were used to study the association of thyroid function or autoimmunity with AFC or day 3 FSH. RESULTS: In the total study population (436 women, 530 AFC measurements), there was no association of thyroid function or TPOAb positivity with AFC. However, TgAb positivity was associated with a higher AFC (mean difference = 3.4 [95% confidence interval (CI) 1.8-5.1], p < 0.001). In women with DOR or unexplained infertility, lower fT3 and TPOAb positivity were associated with a lower AFC (fT3: continuous nonlinear association, p = 0.009; TPOAb positivity: -2.3 follicles [confidence interval -3.8 to -0.5], p = 0.01), while TgAb positivity was not associated with AFC. Neither thyroid function nor thyroid antibody positivity was associated with the day 3 FSH concentration. CONCLUSIONS: This study found that lower fT3 and TPOAb positivity are associated with a lower AFC in women with DOR or unexplained infertility. Future studies are required to replicate these findings and further elucidate the role of TgAbs and underlying mechanisms through which thyroid function and autoimmunity is associated with ovarian reserve.
BACKGROUND: While overt thyroid disease is a well known risk factor for infertility, the potential consequences of mild thyroid dysfunction or thyroid autoimmunity remain unknown. Experimental studies suggest a considerable role for thyroid hormone in the physiological mechanisms of ovarian reserve, but translation of such findings to human studies remains rare. A potential role for thyroid function in female reproduction could be especially relevant when the cause of infertility remains unknown, such as in women with diminished ovarian reserve (DOR) or unexplained infertility. The aims of this study were to investigate the association of thyroid function and autoimmunity with markers of ovarian reserve day 3 follicle-stimulating hormone (FSH) concentrations and antral follicle count (AFC), and to investigate whether thyroid function or autoimmunity may have different effects in women with DOR or unexplained infertility. METHODS: Thyrotropin, free thyroxine, thyroxine, free triiodothyronine (fT3), triiodothyronine, thyroid peroxidase antibodies (TPOAbs), and thyroglobulin antibodies (TgAbs), as well as AFC and the day 3 FSH concentration, were measured among women seeking fertility treatment at the Massachusetts General Hospital Fertility Center. Multiple linear or mixed regression models were used to study the association of thyroid function or autoimmunity with AFC or day 3 FSH. RESULTS: In the total study population (436 women, 530 AFC measurements), there was no association of thyroid function or TPOAb positivity with AFC. However, TgAb positivity was associated with a higher AFC (mean difference = 3.4 [95% confidence interval (CI) 1.8-5.1], p < 0.001). In women with DOR or unexplained infertility, lower fT3 and TPOAb positivity were associated with a lower AFC (fT3: continuous nonlinear association, p = 0.009; TPOAb positivity: -2.3 follicles [confidence interval -3.8 to -0.5], p = 0.01), while TgAb positivity was not associated with AFC. Neither thyroid function nor thyroid antibody positivity was associated with the day 3 FSH concentration. CONCLUSIONS: This study found that lower fT3 and TPOAb positivity are associated with a lower AFC in women with DOR or unexplained infertility. Future studies are required to replicate these findings and further elucidate the role of TgAbs and underlying mechanisms through which thyroid function and autoimmunity is associated with ovarian reserve.
Authors: S Cecconi; N Rucci; M L Scaldaferri; M P Masciulli; G Rossi; C Moretti; M D'Armiento; S Ulisse Journal: Endocrinology Date: 1999-04 Impact factor: 4.736
Authors: D Unuane; B Velkeniers; B Bravenboer; P Drakopoulos; H Tournaye; J Parra; M De Brucker Journal: Hum Reprod Date: 2017-04-01 Impact factor: 6.918
Authors: M N Sakar; A Unal; A E Atay; A G Zebitay; F F Verit; S Demir; M Turfan; B Omer Journal: J Obstet Gynaecol Date: 2015-10-22 Impact factor: 1.246
Authors: M T Rae; O Gubbay; A Kostogiannou; D Price; H O D Critchley; S G Hillier Journal: J Clin Endocrinol Metab Date: 2006-10-10 Impact factor: 5.958
Authors: Carmen Messerlian; Paige L Williams; Jennifer B Ford; Jorge E Chavarro; Lidia Mínguez-Alarcón; Ramace Dadd; Joseph M Braun; Audrey J Gaskins; John D Meeker; Tamarra James-Todd; Yu-Han Chiu; Feiby L Nassan; Irene Souter; John Petrozza; Myra Keller; Thomas L Toth; Antonia M Calafat; Russ Hauser Journal: Hum Reprod Open Date: 2018-02-20
Authors: Julianne Skarha; Lidia Mínguez-Alarcón; Paige L Williams; Tim I M Korevaar; Ralph A de Poortere; Maarten A C Broeren; Jennifer B Ford; Melissa Eliot; Russ Hauser; Joseph M Braun Journal: Environ Int Date: 2018-11-23 Impact factor: 9.621
Authors: S La Vignera; G Defeudis; R Mazzilli; S Medenica; A M Di Tommaso; G Fabozzi; V Zamponi; D Cimadomo; L Rienzi; F M Ubaldi; M Watanabe; A Faggiano Journal: J Endocrinol Invest Date: 2022-08-09 Impact factor: 5.467
Authors: Sarah W Curtis; Metrecia L Terrell; Melanie H Jacobson; Dawayland O Cobb; Victoria S Jiang; Michael F Neblett; Sabrina A Gerkowicz; Jessica B Spencer; M Elizabeth Marder; Dana Boyd Barr; Karen N Conneely; Alicia K Smith; Michele Marcus Journal: Environ Health Date: 2019-08-23 Impact factor: 5.984
Authors: Irene Souter; Andrea Bellavia; Paige L Williams; T I M Korevaar; John D Meeker; Joseph M Braun; Ralph A de Poortere; Maarten A Broeren; Jennifer B Ford; Antonia M Calafat; Jorge E Chavarro; Russ Hauser; Lidia Mínguez-Alarcón Journal: Environ Health Perspect Date: 2020-06-09 Impact factor: 9.031